MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf ...

Novel combination of acimtamig and an allogenic natural killer cell product shows safety and promising objective response ...

We recently published a list of 15 Stocks That Stole The Show Last Week. In this article, we are going to take a look at ...

Exercising during chemotherapy and before surgery may help the body send more immune cells into cancerous tumors, according ...

Fifteen companies skyrocketed by double to triple digits last week, buoyed by fresh company-specific developments and a ...

In developing this automated cell therapy processing platform, Limula’s founders aim to create a disruptive production ...

Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought forward more than a ...

Innate lymphoid cells, which curiously behave like T cells even though they don’t recognize specific antigens, show promise as a potential cancer therapeutic.

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today announced that Andres Isaias, its Chief ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).